Clinical trial

Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

NCT02947620

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Metformin/Atorvastatin 1500mg/40mg, QD Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Metformin 1500mg, QD Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Atorvastatin 40mg, QD Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-08-01

PhasePHASE3

Conditions

Type II Diabetesverified · MONDO: type 2 diabetes mellitus

Dyslipidemiaunresolved

Interventions

Metformin/Atorvastatin 1500mg/40mg, QDDRUG

Metformin 1500mg, QDDRUG

Atorvastatin 40mg, QDDRUG

Sponsors & collaborators

Daewoong Pharmaceutical Co. LTD.lead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02947620 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.